Liposomal amphotericin B twice weekly as antifungal prophylaxis in paediatric haematological malignancy patients

Clinical Microbiology and Infection

Volumn 17, Issue 12, 2011, Pages 1868-1874

  Bochennek, K ^a   Tramsen, L ^a   Schedler, N ^a   Becker, M ^a   Klingebiel, T ^a   Groll, A H ^b   Lehrnbecher, T ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Antifungal prophylaxis; Child; Invasive fungal disease; Liposomal amphotericin B

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CREATININE; LIVER ENZYME; AMPHOTERICIN B; ANTIFUNGAL AGENT; ENZYME;

ARTICLE; BRONCHOSPASM; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPOKALEMIA; MALE; MYCOSIS; NEUTROPENIA; PRIORITY JOURNAL; PROPHYLAXIS; SCHOOL CHILD; SIDE EFFECT; SKIN MANIFESTATION; ADOLESCENT; ADULT; BACTERIOPHAGE; BLOOD; BLOOD DISEASE; CHEMOPROPHYLAXIS; ENZYMOLOGY; INFANT; LIVER; LIVER FUNCTION TEST; METHODOLOGY; PRESCHOOL CHILD; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADOLESCENT; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CHEMOPREVENTION; CHILD; CHILD, PRESCHOOL; CREATININE; ENZYMES; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; INFANT; LIVER; LIVER FUNCTION TESTS; MALE; MYCOSES; PROSPECTIVE STUDIES; SIPHOVIRIDAE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 81255177671     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2011.03483.x     Document Type: Article

References (29)

1. Groll AH, Ritter J, Muller FM. Prevention of fungal infections in children and adolescents with cancer. Klin Padiatr 2001; 213 (suppl 1): A50-A68.
2. Sung L, Lange BJ, Gerbing RB, Alonzo TA, Feusner J. Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemia. Blood 2007; 110: 3532-3539.
3. Cornely OA, Maertens J, Winston DJ et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356: 348-359.
4. Ullmann AJ, Lipton JH, Vesole DH et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356: 335-347.
5. Katz HI. Drug interactions of the newer oral antifungal agents. Br J Dermatol 1999; 141 (suppl 56): 26-32.
6. Kamaluddin M, McNally P, Breatnach F et al. Potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies. Acta Paediatr 2001; 90: 1204-1207.
7. Groll AH, Muller FM, Piscitelli SC, Walsh TJ. Lipid formulations of amphotericin B: clinical perspectives for the management of invasive fungal infections in children with cancer. Klin Padiatr 1998; 210: 264-273.
8. Adler-Moore J, Proffitt RT. Effect of tissue penetration on AmBisome efficacy. Curr Opin Investig Drugs 2003; 4: 179-185.
9. Mehta P, Vinks A, Filipovich A et al. High-dose weekly AmBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study. Biol Blood Marrow Transplant 2006; 12: 235-240.
10. Groll AH, Silling G, Young C et al. Randomized comparison of safety and pharmacokinetics of caspofungin, liposomal amphotericin B, and the combination of both in allogeneic hematopoietic stem cell recipients. Antimicrob Agents Chemother 2010; 54: 4143-4149.
11. Institute NC. Common toxicity criteria version 3.0. Available at: (last accessed 22 July 2010).
12. De Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-1821.
13. Hughes WT, Armstrong D, Bodey GP et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-751.
14. Penack O, Schwartz S, Martus P et al. Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial. Ann Oncol 2006; 18: 1306-1312.
15. Uhlenbrock S, Zimmermann M, Fegeler W, Jurgens H, Ritter J. Liposomal amphotericin B for prophylaxis of invasive fungal infections in high-risk paediatric patients with chemotherapy-related neutropenia: interim analysis of a prospective study. Mycoses 2001; 44: 455-463.
16. Simon A, Besuden M, Vezmar S et al. Itraconazole prophylaxis in pediatric cancer patients receiving conventional chemotherapy or autologous stem cell transplants. Support Care Cancer 2007; 15: 213-220.
17. Allinson K, Kolve H, Gumbinger HG, Vormoor HJ, Ehlert K, Groll AH. Secondary antifungal prophylaxis in paediatric allogeneic haematopoietic stem cell recipients. J Antimicrob Chemother 2008; 61: 734-742.
18. Lehrnbecher T, Laws HJ, Boehm A et al. Compliance with anti-infective preventive measures: a multicentre survey among paediatric oncology patients. Eur J Cancer 2008; 44: 1861-1865.
19. Maertens JA, Madero L, Reilly AF et al. A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. Pediatr Infect Dis J 2010; 29: 415-420.
20. Walsh TJ, Teppler H, Donowitz GR et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1391-1402.
21. van Burik JA, Ratanatharathorn V, Stepan DE et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004; 39: 1407-1416.
22. Kelsey SM, Goldman JM, McCann S et al. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study. Bone Marrow Transplant 1999; 23: 163-168.
23. Andes D. Clinical utility of antifungal pharmacokinetics and pharmacodynamics. Curr Opin Infect Dis 2004; 17: 533-540.
24. Grigull L, Kuehlke O, Beilken A et al. Intravenous and oral sequential itraconazole antifungal prophylaxis in paediatric stem cell transplantation recipients: a pilot study for evaluation of safety and efficacy. Pediatr Transplant 2007; 11: 261-266.
25. Powers JH. Issues in clinical trials of prophylaxis of fungal infections. Clin Infect Dis 2004; 39 (suppl 4): S211-S217.
26. Haiduven D. Nosocomial aspergillosis and building construction. Med Mycol 2009; 47 (suppl. 1): S210-S216.
27. Lehrnbecher T, Bernig T, Hanisch M et al. Common genetic variants in the interleukin-6 and chitotriosidase genes are associated with the risk for serious infection in children undergoing therapy for acute myeloid leukemia. Leukemia 2005; 19: 1745-1750.
28. Sainz J, Perez E, Gomez-Lopera S, Jurado M. IL1 gene cluster polymorphisms and its haplotypes may predict the risk to develop invasive pulmonary aspergillosis and modulate C-reactive protein level. J Clin Immunol 2008; 28: 473-485.
29. Penack O, Reinhold T, Thiel E, Blau IW. Cost-benefit assessment of antifungal prophylaxis with liposomal amphotericin B in neutropenic patients. Onkologie 2007; 30: 621-626.